Fibrocell Science (FCSC) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fibrocell Science Reports Second Quarter 2015 Financial Results and Operational Highlights
August 6, 2015 8:05 AM EDTEXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2015 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.
"We've made significant progress advancing our pipeline," said David Pernock, Chairman and Chief Executive Officer of Fibrocell. "Submission of an IND application for FCX-007our lead orphan gene-therapy product candidate for the... More
